Virological characteristics of the SARS-CoV-2 JN.1 variant
Spike protein mutation Leu455Ser is a hallmark mutation of JN.1: we have recently shown that HK.3 and other flip variants carry Leu455Phe, which contributes to increased transmissibility and immune escape ability compared with the parental EG.5.1 variant.5 Here, we investigated the virological prope...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2024-02, Vol.24 (2), p.e82-e82 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e82 |
|---|---|
| container_issue | 2 |
| container_start_page | e82 |
| container_title | The Lancet infectious diseases |
| container_volume | 24 |
| creator | Kaku, Yu Okumura, Kaho Padilla-Blanco, Miguel Kosugi, Yusuke Uriu, Keiya Hinay, Jr, Alfredo A Chen, Luo Plianchaisuk, Arnon Kobiyama, Kouji Ishii, Ken J Zahradnik, Jiri Ito, Jumpei Sato, Kei |
| description | Spike protein mutation Leu455Ser is a hallmark mutation of JN.1: we have recently shown that HK.3 and other flip variants carry Leu455Phe, which contributes to increased transmissibility and immune escape ability compared with the parental EG.5.1 variant.5 Here, we investigated the virological properties of JN.1. KJI and KS are supported in part by AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA and by AMED SCARDA Program on R&D of new generation vaccine including new modality application. KS received funding from the AMED Research Program on HIV/AIDS, JST CREST, JSPS Core-to-Core Program, The Tokyo Biochemical Research Foundation, and The Mitsubishi Foundation; received consulting fees from Moderna Japan and Takeda Pharmaceutical; and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. JI received funding from JST PRESTO and JSPS KAKENHI Grant-in-Aid for Early-Career Scientists; and received consulting fees and honoraria for lectures from Takeda Pharmaceutical. |
| doi_str_mv | 10.1016/S1473-3099(23)00813-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2919744688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919744688</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-f9a248d471570c7ee83fffc0e8ad7e10f5e9be11f8dce95929fed7bcefd7437a3</originalsourceid><addsrcrecordid>eNpdkE1LAzEQhoMotlZ_grLgpR5SJ5tsk3grxU-KgtVeQ5qd2C3bbk22gv_e7YcePM0wPO_L8BByzqDHgPWvx0xITjlo3U35FYBinMoD0m7OggqRycPtvkNa5CTGOQCTDMQxaXHFlADI2uRmUoSqrD4KZ8vEzWywrsZQxLpwMal8Us8wGQ9ex3RYTWiaPD33WPJlQ2GX9Sk58raMeLafHfJ-d_s2fKCjl_vH4WBEncigpl7bVKhcSJZJcBJRce-9A1Q2l8jAZ6inyJhXuUOd6VR7zOXUoc-l4NLyDunueleh-lxjrM2iiA7L0i6xWkeTaqalEH2lGvTyHzqv1mHZfGc4cC0Z10o3VLajXKhiDOjNKhQLG74NA7ORa7ZyzcacSbnZyjWyyV3s29fTBeZ_qV-b_Ae8jXMq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3039713989</pqid></control><display><type>article</type><title>Virological characteristics of the SARS-CoV-2 JN.1 variant</title><source>Elsevier ScienceDirect Journals</source><creator>Kaku, Yu ; Okumura, Kaho ; Padilla-Blanco, Miguel ; Kosugi, Yusuke ; Uriu, Keiya ; Hinay, Jr, Alfredo A ; Chen, Luo ; Plianchaisuk, Arnon ; Kobiyama, Kouji ; Ishii, Ken J ; Zahradnik, Jiri ; Ito, Jumpei ; Sato, Kei</creator><creatorcontrib>Kaku, Yu ; Okumura, Kaho ; Padilla-Blanco, Miguel ; Kosugi, Yusuke ; Uriu, Keiya ; Hinay, Jr, Alfredo A ; Chen, Luo ; Plianchaisuk, Arnon ; Kobiyama, Kouji ; Ishii, Ken J ; Zahradnik, Jiri ; Ito, Jumpei ; Sato, Kei ; Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><description>Spike protein mutation Leu455Ser is a hallmark mutation of JN.1: we have recently shown that HK.3 and other flip variants carry Leu455Phe, which contributes to increased transmissibility and immune escape ability compared with the parental EG.5.1 variant.5 Here, we investigated the virological properties of JN.1. KJI and KS are supported in part by AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA and by AMED SCARDA Program on R&D of new generation vaccine including new modality application. KS received funding from the AMED Research Program on HIV/AIDS, JST CREST, JSPS Core-to-Core Program, The Tokyo Biochemical Research Foundation, and The Mitsubishi Foundation; received consulting fees from Moderna Japan and Takeda Pharmaceutical; and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. JI received funding from JST PRESTO and JSPS KAKENHI Grant-in-Aid for Early-Career Scientists; and received consulting fees and honoraria for lectures from Takeda Pharmaceutical.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(23)00813-7</identifier><identifier>PMID: 38184005</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Careers ; Consulting ; Funding ; HIV ; Human immunodeficiency virus ; Mutation ; Pharmaceuticals ; Proteins ; R&D ; Research & development ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Vaccines</subject><ispartof>The Lancet infectious diseases, 2024-02, Vol.24 (2), p.e82-e82</ispartof><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-f9a248d471570c7ee83fffc0e8ad7e10f5e9be11f8dce95929fed7bcefd7437a3</citedby><cites>FETCH-LOGICAL-c450t-f9a248d471570c7ee83fffc0e8ad7e10f5e9be11f8dce95929fed7bcefd7437a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38184005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaku, Yu</creatorcontrib><creatorcontrib>Okumura, Kaho</creatorcontrib><creatorcontrib>Padilla-Blanco, Miguel</creatorcontrib><creatorcontrib>Kosugi, Yusuke</creatorcontrib><creatorcontrib>Uriu, Keiya</creatorcontrib><creatorcontrib>Hinay, Jr, Alfredo A</creatorcontrib><creatorcontrib>Chen, Luo</creatorcontrib><creatorcontrib>Plianchaisuk, Arnon</creatorcontrib><creatorcontrib>Kobiyama, Kouji</creatorcontrib><creatorcontrib>Ishii, Ken J</creatorcontrib><creatorcontrib>Zahradnik, Jiri</creatorcontrib><creatorcontrib>Ito, Jumpei</creatorcontrib><creatorcontrib>Sato, Kei</creatorcontrib><creatorcontrib>Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><title>Virological characteristics of the SARS-CoV-2 JN.1 variant</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Spike protein mutation Leu455Ser is a hallmark mutation of JN.1: we have recently shown that HK.3 and other flip variants carry Leu455Phe, which contributes to increased transmissibility and immune escape ability compared with the parental EG.5.1 variant.5 Here, we investigated the virological properties of JN.1. KJI and KS are supported in part by AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA and by AMED SCARDA Program on R&D of new generation vaccine including new modality application. KS received funding from the AMED Research Program on HIV/AIDS, JST CREST, JSPS Core-to-Core Program, The Tokyo Biochemical Research Foundation, and The Mitsubishi Foundation; received consulting fees from Moderna Japan and Takeda Pharmaceutical; and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. JI received funding from JST PRESTO and JSPS KAKENHI Grant-in-Aid for Early-Career Scientists; and received consulting fees and honoraria for lectures from Takeda Pharmaceutical.</description><subject>Careers</subject><subject>Consulting</subject><subject>Funding</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Mutation</subject><subject>Pharmaceuticals</subject><subject>Proteins</subject><subject>R&D</subject><subject>Research & development</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Vaccines</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkE1LAzEQhoMotlZ_grLgpR5SJ5tsk3grxU-KgtVeQ5qd2C3bbk22gv_e7YcePM0wPO_L8BByzqDHgPWvx0xITjlo3U35FYBinMoD0m7OggqRycPtvkNa5CTGOQCTDMQxaXHFlADI2uRmUoSqrD4KZ8vEzWywrsZQxLpwMal8Us8wGQ9ex3RYTWiaPD33WPJlQ2GX9Sk58raMeLafHfJ-d_s2fKCjl_vH4WBEncigpl7bVKhcSJZJcBJRce-9A1Q2l8jAZ6inyJhXuUOd6VR7zOXUoc-l4NLyDunueleh-lxjrM2iiA7L0i6xWkeTaqalEH2lGvTyHzqv1mHZfGc4cC0Z10o3VLajXKhiDOjNKhQLG74NA7ORa7ZyzcacSbnZyjWyyV3s29fTBeZ_qV-b_Ae8jXMq</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Kaku, Yu</creator><creator>Okumura, Kaho</creator><creator>Padilla-Blanco, Miguel</creator><creator>Kosugi, Yusuke</creator><creator>Uriu, Keiya</creator><creator>Hinay, Jr, Alfredo A</creator><creator>Chen, Luo</creator><creator>Plianchaisuk, Arnon</creator><creator>Kobiyama, Kouji</creator><creator>Ishii, Ken J</creator><creator>Zahradnik, Jiri</creator><creator>Ito, Jumpei</creator><creator>Sato, Kei</creator><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>202402</creationdate><title>Virological characteristics of the SARS-CoV-2 JN.1 variant</title><author>Kaku, Yu ; Okumura, Kaho ; Padilla-Blanco, Miguel ; Kosugi, Yusuke ; Uriu, Keiya ; Hinay, Jr, Alfredo A ; Chen, Luo ; Plianchaisuk, Arnon ; Kobiyama, Kouji ; Ishii, Ken J ; Zahradnik, Jiri ; Ito, Jumpei ; Sato, Kei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-f9a248d471570c7ee83fffc0e8ad7e10f5e9be11f8dce95929fed7bcefd7437a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Careers</topic><topic>Consulting</topic><topic>Funding</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Mutation</topic><topic>Pharmaceuticals</topic><topic>Proteins</topic><topic>R&D</topic><topic>Research & development</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaku, Yu</creatorcontrib><creatorcontrib>Okumura, Kaho</creatorcontrib><creatorcontrib>Padilla-Blanco, Miguel</creatorcontrib><creatorcontrib>Kosugi, Yusuke</creatorcontrib><creatorcontrib>Uriu, Keiya</creatorcontrib><creatorcontrib>Hinay, Jr, Alfredo A</creatorcontrib><creatorcontrib>Chen, Luo</creatorcontrib><creatorcontrib>Plianchaisuk, Arnon</creatorcontrib><creatorcontrib>Kobiyama, Kouji</creatorcontrib><creatorcontrib>Ishii, Ken J</creatorcontrib><creatorcontrib>Zahradnik, Jiri</creatorcontrib><creatorcontrib>Ito, Jumpei</creatorcontrib><creatorcontrib>Sato, Kei</creatorcontrib><creatorcontrib>Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaku, Yu</au><au>Okumura, Kaho</au><au>Padilla-Blanco, Miguel</au><au>Kosugi, Yusuke</au><au>Uriu, Keiya</au><au>Hinay, Jr, Alfredo A</au><au>Chen, Luo</au><au>Plianchaisuk, Arnon</au><au>Kobiyama, Kouji</au><au>Ishii, Ken J</au><au>Zahradnik, Jiri</au><au>Ito, Jumpei</au><au>Sato, Kei</au><aucorp>Genotype to Phenotype Japan (G2P-Japan) Consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Virological characteristics of the SARS-CoV-2 JN.1 variant</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2024-02</date><risdate>2024</risdate><volume>24</volume><issue>2</issue><spage>e82</spage><epage>e82</epage><pages>e82-e82</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>Spike protein mutation Leu455Ser is a hallmark mutation of JN.1: we have recently shown that HK.3 and other flip variants carry Leu455Phe, which contributes to increased transmissibility and immune escape ability compared with the parental EG.5.1 variant.5 Here, we investigated the virological properties of JN.1. KJI and KS are supported in part by AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA and by AMED SCARDA Program on R&D of new generation vaccine including new modality application. KS received funding from the AMED Research Program on HIV/AIDS, JST CREST, JSPS Core-to-Core Program, The Tokyo Biochemical Research Foundation, and The Mitsubishi Foundation; received consulting fees from Moderna Japan and Takeda Pharmaceutical; and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. JI received funding from JST PRESTO and JSPS KAKENHI Grant-in-Aid for Early-Career Scientists; and received consulting fees and honoraria for lectures from Takeda Pharmaceutical.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>38184005</pmid><doi>10.1016/S1473-3099(23)00813-7</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2024-02, Vol.24 (2), p.e82-e82 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2919744688 |
| source | Elsevier ScienceDirect Journals |
| subjects | Careers Consulting Funding HIV Human immunodeficiency virus Mutation Pharmaceuticals Proteins R&D Research & development Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccines |
| title | Virological characteristics of the SARS-CoV-2 JN.1 variant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A20%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Virological%20characteristics%20of%20the%20SARS-CoV-2%20JN.1%20variant&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Kaku,%20Yu&rft.aucorp=Genotype%20to%20Phenotype%20Japan%20(G2P-Japan)%20Consortium&rft.date=2024-02&rft.volume=24&rft.issue=2&rft.spage=e82&rft.epage=e82&rft.pages=e82-e82&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(23)00813-7&rft_dat=%3Cproquest_cross%3E2919744688%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3039713989&rft_id=info:pmid/38184005&rfr_iscdi=true |